At a glance
ClinicalIndex Comparison RecordPhase 2Active· 36 enrolled
Drug / intervention
Selpercatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
In Brief
A Phase 2 clinical trial evaluating Selpercatinib for Medullary Thyroid Cancer and 4 related conditions. Active but no longer recruiting, targeting 36 participants across 26 sites in 11 countries.
Detailed Summary
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMedullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
CountriesAustralia, Canada, Denmark, France, Germany, Italy, Japan, South Korea, Spain, United Kingdom, United States
CollaboratorsLoxo Oncology, Inc.
Timeline
Phase 2Active
20192020202120222023202420252026202720282029
First PostedApr 2019
Enrollment StartJun 2019
Primary CompletionNov 2024
TodayJul 2026
Study CompletionMay 2029
First PostedApr 2, 2019
Enrollment StartJun 13, 2019
Primary CompletionNov 8, 2024
Study CompletionMay 1, 2029
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 7.3 years ago
Interventions
Selpercatinibdrug
Oral LOXO-292